QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=F3F7D600406B02DD75B6184B178BF327;jsessionid=734B308E25BB1D0BF012D5904D21F53D;jsessionid=AA46DBBE4EFBB950F5EB0E10747DF686;jsessionid=71F7F9ECB98699CC31E96882268748B9;jsessionid=695634678EEBA2084C39BEC160FF20BA;jsessionid=FF6C5440DEC8CEC4067DA1B1B44B020A (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=F3F7D600406B02DD75B6184B178BF327;jsessionid=734B308E25BB1D0BF012D5904D21F53D;jsessionid=AA46DBBE4EFBB950F5EB0E10747DF686;jsessionid=71F7F9ECB98699CC31E96882268748B9;jsessionid=695634678EEBA2084C39BEC160FF20BA;jsessionid=FF6C5440DEC8CEC4067DA1B1B44B020A